Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00071851 · ClinicalTrials.gov registry record · Phase 1
Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults
A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
- 14
- Study locations
NCT00071851: Completed Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00071851 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 180 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (60% lower). The trial reports 14 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00071851, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to test the safety of and immune response to an HIV-1 vaccine, VRC-HIVDNA009-00-VP, in HIV uninfected participants. Two different doses of the vaccine will be tested.
Conditions Studied
Interventions
- BIOLOGICAL VRC-HIVDNA009-00-VP
Study Locations (14)
New York
- NY Blood Ctr./Union Square CRS - New York
- HIV Prevention & Treatment CRS - New York
- Univ. of Rochester HVTN CRS - Rochester
- NY Blood Ctr./Bronx CRS - The Bronx
Maryland
- Project Brave HIV Vaccine CRS - Baltimore
- Johns Hopkins Bloomberg School of Public Health,Ctr for Immunization Research,Project SAVE-Baltimore - Baltimore
Massachusetts
- Brigham and Women's Hosp. CRS - Boston
- Fenway Community Health Clinical Research Site (FCHCRS) - Boston
Alabama
- Alabama Vaccine CRS - Birmingham
California
- San Francisco Vaccine and Prevention CRS - San Francisco
Missouri
- Saint Louis Univ. School of Medicine, HVTU - St Louis
Rhode Island
- Miriam Hospital's HVTU - Providence
Tennessee
- Vanderbilt Vaccine CRS - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2003-12 |
| Est. Completion | 2005-10 |
| Phase | Phase 1 |
What the finished NCT00071851 record still lists
NCT00071851 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (60% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which VRC-HIVDNA009-00-VP is the first listed.
NCT00071851 lists 14 locations in 9 states (New York, Maryland, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT00071851 about?
NCT00071851 is a clinical study titled "Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults". The purpose of this study is to test the safety of and immune response to an HIV-1 vaccine, VRC-HIVDNA009-00-VP, in HIV uninfected participants. Two different doses of the vaccine will be tested.
What is the current status of trial NCT00071851?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2003-12. Estimated completion is 2005-10.
What conditions does trial NCT00071851 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00071851?
The interventions under investigation include: VRC-HIVDNA009-00-VP (BIOLOGICAL).
Who is sponsoring clinical trial NCT00071851?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00071851 being conducted?
This trial has 14 study locations across Alabama, California, Maryland, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00071851's enrollment target sits among peer trials
180 189th of 542 higher than 350 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia